{"id":797985,"date":"2025-01-06T08:33:33","date_gmt":"2025-01-06T13:33:33","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/enveric-biosciences-to-present-at-and-participate-in-panel-discussion-at-sachs-associates-8th-annual-neuroscience-innovation-forum-during-j-p-morgan-week-2025\/"},"modified":"2025-01-06T08:33:33","modified_gmt":"2025-01-06T13:33:33","slug":"enveric-biosciences-to-present-at-and-participate-in-panel-discussion-at-sachs-associates-8th-annual-neuroscience-innovation-forum-during-j-p-morgan-week-2025","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/enveric-biosciences-to-present-at-and-participate-in-panel-discussion-at-sachs-associates-8th-annual-neuroscience-innovation-forum-during-j-p-morgan-week-2025\/","title":{"rendered":"Enveric Biosciences to Present at and Participate in Panel Discussion at Sachs Associates 8th Annual Neuroscience Innovation Forum During \u201cJ.P. Morgan Week 2025\u201d"},"content":{"rendered":"

<\/p>\n

Enveric Biosciences to Present at and Participate in Panel Discussion at Sachs Associates 8th<\/sup> Annual Neuroscience Innovation Forum During \u201cJ.P. Morgan Week 2025\u201d<\/b><\/p>\n

Management to meet with investors and potential partners during Biotech Showcase 2025<\/i><\/p>\n

CAMBRIDGE, Mass.–(BUSINESS WIRE<\/a>)–Enveric Biosciences<\/a> (NASDAQ: ENVB) (\u201cEnveric\u201d or the \u201cCompany\u201d), a biotechnology company dedicated to the development of novel neuroplastogenic small-molecule therapeutics for the treatment of anxiety, depression, and addiction disorders, today announced Joseph Tucker, Ph.D., CEO, will participate in a panel discussion and present at the Sachs Associates 8th<\/sup> Annual Neuroscience Innovation Forum on January 12, 2025. Additionally, Enveric will attend Biotech Showcase 2025 from January 13-15, 2025. Both conferences are being held in San Francisco during \u201cJ.P. Morgan Week 2025.\u201d<\/p>\n

\nDuring the events, members of Enveric\u2019s management team will conduct one-on-one meetings with registered investors and potential partners, showcasing the company\u2019s business and clinical development strategy, recent corporate achievements, and anticipated milestones.<\/p>\n

\nDetails are as follows:<\/p>\n\n\n\n\n\n\n
\n

Event:<\/b><\/p>\n<\/td>\n

\n

Sachs Associates 8th Annual Neuroscience Innovation Forum<\/b><\/p>\n<\/td>\n<\/tr>\n

\n

Panel:<\/b><\/p>\n<\/td>\n

\n

Future of Psychedelics – <\/i>January 12, 2025, at 2:20 p.m., PDT<\/p>\n<\/td>\n<\/tr>\n

\n

Presentation:<\/b><\/p>\n<\/td>\n

\n

\n4:05 p.m., PDT, January 12, 2025 – Track E – Room Heritage<\/p>\n<\/td>\n<\/tr>\n

\n

Location:<\/b><\/p>\n<\/td>\n

\n

\nMarines\u2019 Memorial Club<\/p>\n<\/td>\n<\/tr>\n

\n

Registration:<\/b><\/p>\n<\/td>\n

\n

https:\/\/www.sachsforum.com\/8nif-registration.html<\/a><\/p>\n<\/td>\n<\/tr>\n<\/table>\n\n\n\n\n\n
\n

Event:<\/b><\/p>\n<\/td>\n

\n

Biotech Showcase 2025<\/b><\/p>\n<\/td>\n<\/tr>\n

\n

Date and Time:<\/b><\/p>\n<\/td>\n

\n

\nJanuary 13-15, 2025<\/p>\n<\/td>\n<\/tr>\n

\n

Location:<\/b><\/p>\n<\/td>\n

\n

\nHilton San Francisco Union Square<\/p>\n<\/td>\n<\/tr>\n

\n

Registration:<\/b><\/p>\n<\/td>\n

\n

https:\/\/informaconnect.com\/biotech-showcase\/registration-options\/<\/a><\/p>\n<\/td>\n<\/tr>\n<\/table>\n

About Enveric Biosciences<\/b><\/p>\n

\nEnveric Biosciences (NASDAQ: ENVB) is a biotechnology company dedicated to the development of novel neuroplastogenic small-molecule therapeutics for the treatment of depression, anxiety, and addiction disorders. Leveraging its unique discovery and development platform, Psybrary\u2122, Enveric has created a robust intellectual property portfolio of new chemical entities for specific mental health indications. Enveric\u2019s lead molecule, EB-003, is a potential first-in-class neuroplastogen designed to promote neuroplasticity, without inducing hallucinations, in patients suffering from difficult-to-address mental health disorders. Enveric is focused on advancing EB-003 towards clinical trials for the treatment of neuropsychiatric disorders while out-licensing all other novel, patented Psybrary\u2122 drug candidates to third-party licensees advancing non-competitive market strategies for patient care. Enveric is headquartered in Naples, FL with offices in Cambridge, MA and Calgary, AB Canada. For more information, please visit www.enveric.com<\/a>.<\/p>\n

\nForward-Looking Statements<\/p>\n

\nThis press release contains forward-looking statements and forward-looking information within the meaning of applicable securities laws. These statements relate to future events or future performance. All statements other than statements of historical fact may be forward-looking statements or information. Generally, forward-looking statements and information may be identified by the use of forward-looking terminology such as \u201cplans,\u201d \u201cexpects\u201d or \u201cdoes not expect,\u201d \u201cproposes,\u201d \u201cbudgets,\u201d \u201cexplores,\u201d \u201cschedules,\u201d \u201cseeks,\u201d \u201cestimates,\u201d \u201cforecasts,\u201d \u201cintends,\u201d \u201canticipates\u201d or \u201cdoes not anticipate,\u201d or \u201cbelieves,\u201d or variations of such words and phrases, or by the use of words or phrases which state that certain actions, events or results may, could, should, would, or might occur or be achieved. Forward-looking statements may include statements regarding beliefs, plans, expectations, or intentions regarding the future and are based on the beliefs of management as well as assumptions made by and information currently available to management. Actual results could differ materially from those contemplated by the forward-looking statements as a result of certain factors, including, but not limited to, the ability of Enveric to: successfully outlicense patented Psybrary\u2122 drug candidates to third-party licensees; negotiate and finalize definitive agreements based on any of its out-licensing term sheets and for licensees to perform pursuant to the terms thereof; finalize and submit its IND filing to the U.S. Food and Drug Administration; carry out successful clinical programs; achieve the value creation contemplated by technical developments; avoid delays in planned clinical trials; establish that potential products are efficacious or safe in preclinical or clinical trials; establish or maintain collaborations for the development of therapeutic candidates; obtain appropriate or necessary governmental approvals to market potential products; obtain future funding for product development and working capital on commercially reasonable terms; scale-up manufacture of product candidates; respond to changes in the size and nature of competitors; hire and retain key executives and scientists; secure and enforce legal rights related to Enveric\u2019s products, including patent protection; identify and pursue alternative routes to capture value from its research and development pipeline assets; continue as a going concern; and manage its future growth effectively.<\/p>\n

\nA discussion of these and other factors, including risks and uncertainties with respect to Enveric, is set forth in Enveric\u2019s filings with the Securities and Exchange Commission, including Enveric\u2019s Annual Report on Form 10-K and its Quarterly Reports on Form 10-Q. Enveric disclaims any intention or obligation to revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.<\/p>\n

\"\"<\/p>\n

View source version on businesswire.com: <\/span>https:\/\/www.businesswire.com\/news\/home\/20250106395672\/en\/<\/a><\/span><\/p>\n

\nInvestor Relations
\n
Tiberend Strategic Advisors, Inc.
\n<\/a>
David Irish
\n
(231) 632-0002
\n
dirish@tiberend.com<\/a><\/p>\n

\nMedia Relations
\n
Tiberend Strategic Advisors, Inc.
\n<\/a>
Casey McDonald
\n
(646) 577-8520
\n
cmcdonald@tiberend.com<\/a><\/p>\n

KEYWORDS:<\/b> California Massachusetts United States North America<\/p>\n

INDUSTRY KEYWORDS:<\/b> Mental Health Finance Neurology Clinical Trials Professional Services Biotechnology Pharmaceutical Health Science Other Science<\/p>\n

MEDIA:<\/b><\/p>\n\n\n\n\n
Logo<\/b><\/font><\/td>\n<\/tr>\n
\"Logo\"<\/td>\n<\/tr>\n
<\/font><\/td>\n<\/tr>\n<\/table>\n","protected":false},"excerpt":{"rendered":"

Enveric Biosciences to Present at and Participate in Panel Discussion at Sachs Associates 8th Annual Neuroscience Innovation Forum During \u201cJ.P. Morgan Week 2025\u201d Management to meet with investors and potential partners during Biotech Showcase 2025 CAMBRIDGE, Mass.–(BUSINESS WIRE)–Enveric Biosciences (NASDAQ: ENVB) (\u201cEnveric\u201d or the \u201cCompany\u201d), a biotechnology company dedicated to the development of novel neuroplastogenic small-molecule therapeutics for the treatment of anxiety, depression, and addiction disorders, today announced Joseph Tucker, Ph.D., CEO, will participate in a panel discussion and present at the Sachs Associates 8th Annual Neuroscience Innovation Forum on January 12, 2025. Additionally, Enveric will attend Biotech Showcase 2025 from January 13-15, 2025. Both conferences are being held in San Francisco during \u201cJ.P. Morgan Week 2025.\u201d During the events, … <\/p>\n

Continue reading “Enveric Biosciences to Present at and Participate in Panel Discussion at Sachs Associates 8th Annual Neuroscience Innovation Forum During \u201cJ.P. Morgan Week 2025\u201d”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-797985","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nEnveric Biosciences to Present at and Participate in Panel Discussion at Sachs Associates 8th Annual Neuroscience Innovation Forum During \u201cJ.P. Morgan Week 2025\u201d - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/enveric-biosciences-to-present-at-and-participate-in-panel-discussion-at-sachs-associates-8th-annual-neuroscience-innovation-forum-during-j-p-morgan-week-2025\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Enveric Biosciences to Present at and Participate in Panel Discussion at Sachs Associates 8th Annual Neuroscience Innovation Forum During \u201cJ.P. Morgan Week 2025\u201d - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Enveric Biosciences to Present at and Participate in Panel Discussion at Sachs Associates 8th Annual Neuroscience Innovation Forum During \u201cJ.P. Morgan Week 2025\u201d Management to meet with investors and potential partners during Biotech Showcase 2025 CAMBRIDGE, Mass.–(BUSINESS WIRE)–Enveric Biosciences (NASDAQ: ENVB) (\u201cEnveric\u201d or the \u201cCompany\u201d), a biotechnology company dedicated to the development of novel neuroplastogenic small-molecule therapeutics for the treatment of anxiety, depression, and addiction disorders, today announced Joseph Tucker, Ph.D., CEO, will participate in a panel discussion and present at the Sachs Associates 8th Annual Neuroscience Innovation Forum on January 12, 2025. Additionally, Enveric will attend Biotech Showcase 2025 from January 13-15, 2025. Both conferences are being held in San Francisco during \u201cJ.P. Morgan Week 2025.\u201d During the events, … Continue reading "Enveric Biosciences to Present at and Participate in Panel Discussion at Sachs Associates 8th Annual Neuroscience Innovation Forum During \u201cJ.P. Morgan Week 2025\u201d"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/enveric-biosciences-to-present-at-and-participate-in-panel-discussion-at-sachs-associates-8th-annual-neuroscience-innovation-forum-during-j-p-morgan-week-2025\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2025-01-06T13:33:33+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20250106395672r1&sid=flmnd&distro=nx&lang=en\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/enveric-biosciences-to-present-at-and-participate-in-panel-discussion-at-sachs-associates-8th-annual-neuroscience-innovation-forum-during-j-p-morgan-week-2025\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/enveric-biosciences-to-present-at-and-participate-in-panel-discussion-at-sachs-associates-8th-annual-neuroscience-innovation-forum-during-j-p-morgan-week-2025\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Enveric Biosciences to Present at and Participate in Panel Discussion at Sachs Associates 8th Annual Neuroscience Innovation Forum During \u201cJ.P. Morgan Week 2025\u201d\",\"datePublished\":\"2025-01-06T13:33:33+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/enveric-biosciences-to-present-at-and-participate-in-panel-discussion-at-sachs-associates-8th-annual-neuroscience-innovation-forum-during-j-p-morgan-week-2025\\\/\"},\"wordCount\":850,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/enveric-biosciences-to-present-at-and-participate-in-panel-discussion-at-sachs-associates-8th-annual-neuroscience-innovation-forum-during-j-p-morgan-week-2025\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20250106395672r1&sid=flmnd&distro=nx&lang=en\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/enveric-biosciences-to-present-at-and-participate-in-panel-discussion-at-sachs-associates-8th-annual-neuroscience-innovation-forum-during-j-p-morgan-week-2025\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/enveric-biosciences-to-present-at-and-participate-in-panel-discussion-at-sachs-associates-8th-annual-neuroscience-innovation-forum-during-j-p-morgan-week-2025\\\/\",\"name\":\"Enveric Biosciences to Present at and Participate in Panel Discussion at Sachs Associates 8th Annual Neuroscience Innovation Forum During \u201cJ.P. Morgan Week 2025\u201d - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/enveric-biosciences-to-present-at-and-participate-in-panel-discussion-at-sachs-associates-8th-annual-neuroscience-innovation-forum-during-j-p-morgan-week-2025\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/enveric-biosciences-to-present-at-and-participate-in-panel-discussion-at-sachs-associates-8th-annual-neuroscience-innovation-forum-during-j-p-morgan-week-2025\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20250106395672r1&sid=flmnd&distro=nx&lang=en\",\"datePublished\":\"2025-01-06T13:33:33+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/enveric-biosciences-to-present-at-and-participate-in-panel-discussion-at-sachs-associates-8th-annual-neuroscience-innovation-forum-during-j-p-morgan-week-2025\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/enveric-biosciences-to-present-at-and-participate-in-panel-discussion-at-sachs-associates-8th-annual-neuroscience-innovation-forum-during-j-p-morgan-week-2025\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/enveric-biosciences-to-present-at-and-participate-in-panel-discussion-at-sachs-associates-8th-annual-neuroscience-innovation-forum-during-j-p-morgan-week-2025\\\/#primaryimage\",\"url\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20250106395672r1&sid=flmnd&distro=nx&lang=en\",\"contentUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20250106395672r1&sid=flmnd&distro=nx&lang=en\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/enveric-biosciences-to-present-at-and-participate-in-panel-discussion-at-sachs-associates-8th-annual-neuroscience-innovation-forum-during-j-p-morgan-week-2025\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Enveric Biosciences to Present at and Participate in Panel Discussion at Sachs Associates 8th Annual Neuroscience Innovation Forum During \u201cJ.P. Morgan Week 2025\u201d\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Enveric Biosciences to Present at and Participate in Panel Discussion at Sachs Associates 8th Annual Neuroscience Innovation Forum During \u201cJ.P. Morgan Week 2025\u201d - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/enveric-biosciences-to-present-at-and-participate-in-panel-discussion-at-sachs-associates-8th-annual-neuroscience-innovation-forum-during-j-p-morgan-week-2025\/","og_locale":"en_US","og_type":"article","og_title":"Enveric Biosciences to Present at and Participate in Panel Discussion at Sachs Associates 8th Annual Neuroscience Innovation Forum During \u201cJ.P. Morgan Week 2025\u201d - Market Newsdesk","og_description":"Enveric Biosciences to Present at and Participate in Panel Discussion at Sachs Associates 8th Annual Neuroscience Innovation Forum During \u201cJ.P. Morgan Week 2025\u201d Management to meet with investors and potential partners during Biotech Showcase 2025 CAMBRIDGE, Mass.–(BUSINESS WIRE)–Enveric Biosciences (NASDAQ: ENVB) (\u201cEnveric\u201d or the \u201cCompany\u201d), a biotechnology company dedicated to the development of novel neuroplastogenic small-molecule therapeutics for the treatment of anxiety, depression, and addiction disorders, today announced Joseph Tucker, Ph.D., CEO, will participate in a panel discussion and present at the Sachs Associates 8th Annual Neuroscience Innovation Forum on January 12, 2025. Additionally, Enveric will attend Biotech Showcase 2025 from January 13-15, 2025. Both conferences are being held in San Francisco during \u201cJ.P. Morgan Week 2025.\u201d During the events, … Continue reading \"Enveric Biosciences to Present at and Participate in Panel Discussion at Sachs Associates 8th Annual Neuroscience Innovation Forum During \u201cJ.P. Morgan Week 2025\u201d\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/enveric-biosciences-to-present-at-and-participate-in-panel-discussion-at-sachs-associates-8th-annual-neuroscience-innovation-forum-during-j-p-morgan-week-2025\/","og_site_name":"Market Newsdesk","article_published_time":"2025-01-06T13:33:33+00:00","og_image":[{"url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20250106395672r1&sid=flmnd&distro=nx&lang=en","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/enveric-biosciences-to-present-at-and-participate-in-panel-discussion-at-sachs-associates-8th-annual-neuroscience-innovation-forum-during-j-p-morgan-week-2025\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/enveric-biosciences-to-present-at-and-participate-in-panel-discussion-at-sachs-associates-8th-annual-neuroscience-innovation-forum-during-j-p-morgan-week-2025\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Enveric Biosciences to Present at and Participate in Panel Discussion at Sachs Associates 8th Annual Neuroscience Innovation Forum During \u201cJ.P. Morgan Week 2025\u201d","datePublished":"2025-01-06T13:33:33+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/enveric-biosciences-to-present-at-and-participate-in-panel-discussion-at-sachs-associates-8th-annual-neuroscience-innovation-forum-during-j-p-morgan-week-2025\/"},"wordCount":850,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/enveric-biosciences-to-present-at-and-participate-in-panel-discussion-at-sachs-associates-8th-annual-neuroscience-innovation-forum-during-j-p-morgan-week-2025\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20250106395672r1&sid=flmnd&distro=nx&lang=en","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/enveric-biosciences-to-present-at-and-participate-in-panel-discussion-at-sachs-associates-8th-annual-neuroscience-innovation-forum-during-j-p-morgan-week-2025\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/enveric-biosciences-to-present-at-and-participate-in-panel-discussion-at-sachs-associates-8th-annual-neuroscience-innovation-forum-during-j-p-morgan-week-2025\/","name":"Enveric Biosciences to Present at and Participate in Panel Discussion at Sachs Associates 8th Annual Neuroscience Innovation Forum During \u201cJ.P. Morgan Week 2025\u201d - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/enveric-biosciences-to-present-at-and-participate-in-panel-discussion-at-sachs-associates-8th-annual-neuroscience-innovation-forum-during-j-p-morgan-week-2025\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/enveric-biosciences-to-present-at-and-participate-in-panel-discussion-at-sachs-associates-8th-annual-neuroscience-innovation-forum-during-j-p-morgan-week-2025\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20250106395672r1&sid=flmnd&distro=nx&lang=en","datePublished":"2025-01-06T13:33:33+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/enveric-biosciences-to-present-at-and-participate-in-panel-discussion-at-sachs-associates-8th-annual-neuroscience-innovation-forum-during-j-p-morgan-week-2025\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/enveric-biosciences-to-present-at-and-participate-in-panel-discussion-at-sachs-associates-8th-annual-neuroscience-innovation-forum-during-j-p-morgan-week-2025\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/enveric-biosciences-to-present-at-and-participate-in-panel-discussion-at-sachs-associates-8th-annual-neuroscience-innovation-forum-during-j-p-morgan-week-2025\/#primaryimage","url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20250106395672r1&sid=flmnd&distro=nx&lang=en","contentUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20250106395672r1&sid=flmnd&distro=nx&lang=en"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/enveric-biosciences-to-present-at-and-participate-in-panel-discussion-at-sachs-associates-8th-annual-neuroscience-innovation-forum-during-j-p-morgan-week-2025\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Enveric Biosciences to Present at and Participate in Panel Discussion at Sachs Associates 8th Annual Neuroscience Innovation Forum During \u201cJ.P. Morgan Week 2025\u201d"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/797985","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=797985"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/797985\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=797985"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=797985"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=797985"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}